Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34657509)
Watch
English
Chronic myeloid leukaemia
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
review article
1 reference
stated in
Europe PubMed Central
title
Chronic myeloid leukaemia.
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
main subject
leukemia
1 reference
based on heuristic
inferred from title
author
Andreas Hochhaus
object named as
Andreas Hochhaus
series ordinal
2
0 references
Michele Baccarani
series ordinal
3
object named as
Michele Baccarani
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
author name string
Rüdiger Hehlmann
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
European LeukemiaNet
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
language of work or name
English
0 references
publication date
1 July 2007
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
volume
370
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
page(s)
342-350
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
issue
9584
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
cites work
Chronic myeloid leukemia: a model for oncology
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The story of chronic myeloid leukaemia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chromosomal localization of human cellular homologues of two viral oncogenes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tyrosine kinases as targets for cancer therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pregnancy among patients with chronic myeloid leukemia treated with imatinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Induction of centrosome and chromosome aberrations by imatinib in vitro
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon-alfa for chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cytogenetic response to prior treatment with interferon-α is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The German competence network ‘Acute and chronic leukemias’
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Overriding imatinib resistance with a novel ABL kinase inhibitor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961165-9
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(07)61165-9
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
PubMed ID
17662883
1 reference
stated in
Europe PubMed Central
PubMed ID
17662883
retrieved
3 August 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
